Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITY OF SOUTH DAKOTA holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which points to a focused and manageable level of active prosecution. This action is being reviewed by 1 distinct examiner, meaning the university's current success at the USPTO depends on a single line of communication. Additionally, the portfolio is active in 1 distinct art unit, suggesting that the university's research is currently being examined within a specific pharmaceutical sub-specialty.
The busiest examiner for the university is WANG, CHANG YU, who is overseeing the 1 pending office action. Since WANG, CHANG YU is the only examiner with an active case, his individual examination style is of paramount importance to the university. For a practitioner, the existence of 1 busiest examiner pending case means that resources can be dedicated to addressing the specific issues raised by this official. The concentration in 1 distinct art unit also simplifies the prosecution process by ensuring that the legal team only needs to navigate the rules and precedents of a single administrative division.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917264 | COMPOSITIONS COMPRISING RECOMBINANT EPO AND METHODS OF USE THEREOF | WANG, CHANG YU | 51d overdue |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17917264 | COMPOSITIONS COMPRISING RECOMBINANT EPO AND METHODS OF USE THEREOF | WANG, CHANG YU | 1675 | §103 | Final Rejection | 51d overdue | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY OF SOUTH DAKOTA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chang Yu Wang has the most, with 1 of UNIVERSITY OF SOUTH DAKOTA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
